Healthcare provider profile · identity verified

Manuel Morlote, MD

Cardiology · NEW YORK, NY · NPI 1316910136

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	889	266
Metoprolol Succinate	Metoprolol Succinate	810	227
Rosuvastatin Calcium	Rosuvastatin Calcium	798	250
Amlodipine Besylate	Amlodipine Besylate	511	146
Losartan Potassium	Losartan Potassium	483	153
Eliquis	Apixaban	446	89
Ezetimibe	Ezetimibe	312	100
Jardiance	Empagliflozin	280	65
Levothyroxine Sodium	Levothyroxine Sodium	263	75
Clopidogrel	Clopidogrel Bisulfate	224	68
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	189	57
Carvedilol	Carvedilol	181	50
Doxazosin Mesylate	Doxazosin Mesylate	176	46
Entresto	Sacubitril/Valsartan	164	37
Olmesartan Medoxomil	Olmesartan Medoxomil	164	61
Furosemide	Furosemide	162	44
Metformin Hcl	Metformin Hcl	162	51
Omeprazole	Omeprazole	141	48
Hydrochlorothiazide	Hydrochlorothiazide	135	45
Ramipril	Ramipril	135	39
Nebivolol Hcl	Nebivolol Hcl	132	35
Vitamin D2	Ergocalciferol (Vitamin D2)	132	32
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	115	35
Xarelto	Rivaroxaban	114	24
Lisinopril	Lisinopril	113	37
Olmesartan-Amlodipine-Hctz	Olmesartan/Amlodipin/Hcthiazid	111	28
Vascepa	Icosapent Ethyl	111	29
Atenolol	Atenolol	101	27
Januvia	Sitagliptin Phosphate	101	18
Spironolactone	Spironolactone	86	28
Ozempic	Semaglutide	77	16
Famotidine	Famotidine	75	22
Metformin Hcl Er	Metformin Hcl	75	24
Pantoprazole Sodium	Pantoprazole Sodium	75	19
Amlodipine-Olmesartan	Amlodipine Bes/Olmesartan Med	68	23
Simvastatin	Simvastatin	68	22
Nifedipine Er	Nifedipine	66	19
Warfarin Sodium	Warfarin Sodium	63	suppressed
Ranolazine Er	Ranolazine	62	13
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	60	19
Gabapentin	Gabapentin	59	19
Montelukast Sodium	Montelukast Sodium	52	17
Pravastatin Sodium	Pravastatin Sodium	51	17
Telmisartan	Telmisartan	51	11
Valsartan	Valsartan	51	16
Eplerenone	Eplerenone	50	13
Hydralazine Hcl	Hydralazine Hcl	50	17
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	49	11
Praluent Pen	Alirocumab	48	suppressed
Fluticasone Propionate	Fluticasone Propionate	43	11
Chlorthalidone	Chlorthalidone	41	12
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	40	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	39	suppressed
Meclizine Hcl	Meclizine Hcl	39	14
Farxiga	Dapagliflozin Propanediol	38	suppressed
Ammonium Lactate	Ammonium Lactate	37	13
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	36	11
Potassium Chloride	Potassium Chloride	35	suppressed
Icosapent Ethyl	Icosapent Ethyl	34	12
Alprazolam	Alprazolam	33	suppressed
Enalapril Maleate	Enalapril Maleate	33	13
Tamsulosin Hcl	Tamsulosin Hcl	33	14
Amiodarone Hcl	Amiodarone Hcl	32	12
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	32	11
Pioglitazone Hcl	Pioglitazone Hcl	31	suppressed
Glipizide Er	Glipizide	29	suppressed
Torsemide	Torsemide	29	suppressed
Donepezil Hcl	Donepezil Hcl	28	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	27	11
Dabigatran Etexilate	Dabigatran Etexilate Mesylate	27	suppressed
Repatha Sureclick	Evolocumab	26	suppressed
Sertraline Hcl	Sertraline Hcl	25	suppressed
Trazodone Hcl	Trazodone Hcl	25	suppressed
Spironolactone-Hctz	Spironolact/Hydrochlorothiazid	24	suppressed
Bumetanide	Bumetanide	23	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	23	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	22	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	22	suppressed
Cilostazol	Cilostazol	21	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	21	suppressed
Tramadol Hcl	Tramadol Hcl	21	suppressed
Digoxin	Digoxin	20	suppressed
Pregabalin	Pregabalin	20	suppressed
Propranolol Hcl Er	Propranolol Hcl	19	suppressed
Telmisartan-Hydrochlorothiazid	Telmisartan/Hydrochlorothiazid	19	suppressed
Benazepril Hcl	Benazepril Hcl	17	suppressed
Livalo	Pitavastatin Calcium	17	suppressed
Pitavastatin Calcium	Pitavastatin Calcium	17	suppressed
Allopurinol	Allopurinol	16	suppressed
Dexlansoprazole Dr	Dexlansoprazole	16	suppressed
Diclofenac Sodium	Diclofenac Sodium	16	suppressed
Amoxicillin	Amoxicillin	15	suppressed
Finasteride	Finasteride	15	suppressed
Metolazone	Metolazone	15	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	14	suppressed
Bystolic	Nebivolol Hcl	14	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	14	suppressed
Breo Ellipta	Fluticasone/Vilanterol	13	suppressed
Diltiazem Hcl	Diltiazem Hcl	13	suppressed
Glimepiride	Glimepiride	13	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	13	suppressed
Meloxicam	Meloxicam	13	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	13	suppressed
Ventolin Hfa	Albuterol Sulfate	13	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	12	suppressed
Alendronate Sodium	Alendronate Sodium	11	suppressed
Azithromycin	Azithromycin	11	suppressed
Clonazepam	Clonazepam	11	suppressed
Labetalol Hcl	Labetalol Hcl	11	suppressed
Lorazepam	Lorazepam	11	suppressed
Mounjaro	Tirzepatide	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Silver Sulfadiazine	Silver Sulfadiazine	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error